DaraVMP is a new standard of care for ND multiple myeloma not eligible for transplant that can be potentially affordable in many countries due to the fact that bortezomib, melphalan and prednisone is not an expensive combination so dara would be the only new and more expensive agent
Response: The CENTAURUS study was a randomized phase II trial evaluating 3 different dosing schedules of daratumumab for the treatment of smoldering multiple myeloma at intermediate to high risk of progression to active disease
The method of head and neck cancer care delivery is potentially modifiable through targeted interventions and thus represents an important target that can be manipulated to improve survival for head and neck cancer patients.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.